The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Sun., Apr. 18, 4:45 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #74. Bio-Rad MorphoSys's Research and Diagnostic Antibody Business AbD Serotec

Acquirer: Bio-Rad (NYSE:BIO)
Acquiree: MorphoSys's Research and Diagnostic Antibody Business AbD Serotec
Details: MorphoSys AG / Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec.

Bio-Rad Laboratories is a manufacturer and distributor of its own life science research and clinical diagnostics products. Co.'s business is organized into two reportable segments: Life Science, which develops, manufactures, sells and services reagents, apparatus and instruments used for biological research; and Clinical Diagnostics, which develops, manufactures, sells and services automated test systems, informatics systems, test kits and quality controls for the healthcare market. Co. sells its products and services to a client base comprised of scientific research, healthcare, education and government customers.

BIO SEC Filing Email Alerts Service


Open the BIO Page at The Online Investor »

Company Name: 
Bio-Rad Laboratories Inc
Stock buyback: 
BIO buyback
Website: 
www.bio-rad.com
Sector: 
Biotechnology
Number of ETFs Holding BIO: 
95
Total Market Value Held by ETFs: 
$2.12B
Total Market Capitalization: 
$15.16B
% of Market Cap. Held by ETFs: 
13.96%
 

Open the BIO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
97th percentile
(ranked higher than approx. 97% of all stocks covered)

Analysts' Target Price:
BIO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 74 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.